Dovitinib

10 mg

Cat. No.: 80-Z03

$99.00

Dovitinib is a small molecule receptor tyrosine kinase inhibitor. It potently inhibits receptor tyrosine kinases including FLT3, c-KIT, CSF-1R/c-fms, FGFR1, FGFR3, VEGFR1/Flt1,VEGFR2/Flk1, VEGFR3/Flt4, PDGFRβ, and PDGFRα. Dovitinib shows both antitumor and antiangiogenic activities in vivo. It has also been used as an  effective treatment in xenograft mouse models of FGFR3 multiple myeloma (MM).  

Categories: ,

Details

TECHNICAL INFORMATION

Other Names: CHIR-258, TKI-258

Chemical Formula: C21H21FN6O•C3H6O3

CAS Number: 692737-80-7

Molecular Weight: 482.51

Purity:  >98%

Appearance:  a crystalline solid  

Solubility: DMSO

 

STORAGE AND HANDLING

Storage: Store at 4°C and protected from light. Following reconstitution, store  aliquots at -20°C. 

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

 

PRODUCT USE

Soluble in DMSO at 25 mg/ml. If precipitate is observed, vortex for 5 minutes. For most cells, the maximum tolerance to DMSO is less than 0.5%. 

References

Chase et al. (2007) Activity of TKI258 against primary cells and cell lines with FGFR1-fusion genes associated with the 8p11 myeloproliferative syndrome. Blood. 110(10):3729-34.

Trudel et al. (2005) CHIR-258 | a novel | multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood. 105(7):2491-8.

Azab et al. (2011) FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation. Clin Cancer Res. 17(13):4389-99.

Tech Docs

Product Specifications

MSDS

Related products